Cannabis Law Report

AUGUST 12, 2021

Net loss for the six months ended 30 June 2021 was $30.2 Net loss for the six months ended 30 June 2021 was $30.2 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. The analogy would be this.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JUNE 2, 2021

Researchers studying the efficacy of marijuana treatments for veterans’ mental health now have access to $20 million in marijuana tax revenue to fund clinical trials. The Marijuana Regulatory Agency issued a request for proposals for the 2021 Veteran Marijuana Research Grant Program on Tuesday, June 1. Between Dec.

Clinical Trials 105

Clinical Trials Marijuana Recreational Collective 105

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes. “We

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

NOVEMBER 26, 2021

(NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2021. On September 30, 2021, Can-Fite had approximately $13.3 Fortified Balance Sheet.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.)

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

AUGUST 17, 2021

Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. During the trial, patients with focal seizures (n=19) showed a median 25.2 We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. For instance, as of June 2021, InMed Pharmaceuticals, Inc.,

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. The data also shows that prior to 2020, people between 45 and 52 years old had the highest incidence of prescriptions. Queensland was the source of 51% of prescriptions between 2016 and 2021.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The trial’s secondary endpoints including pharmacokinetics, genotyping, Neuropsychiatric Inventory (NPI), and measurement of suicide severity, have also been completed.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Puff Puff Post

DECEMBER 28, 2018

An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. The Current Treatments for Autism. Most education-based autism treatment is focused on teaching developing children self-care, communicative, and social skills. As it sits, only a few methods of treating autism are available.

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

AUGUST 10, 2021

CSE: LOAN ) (FSE: O3X) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“Global” or the “Company”) is pleased to announce the signing of a definitive agreement on August 6th 2021 memorializing the Global Wellness Strategies , Inc. binding letter of intent signed on July 12th 2021 to purchase certain assets of Cannvalate Pty Ltd. (“CV”)

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

NOVEMBER 23, 2021

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. The new patent, US Patent … London, UK – 23 November 2021.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

DECEMBER 26, 2021

December 17, 2021 ·. – December 16, 2021) – Entheon Biomedical Corp. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. US Provisional Patent Filed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Canna Law Blog

NOVEMBER 6, 2021

Instead, qualifying evidence may come from adequate and well-controlled clinical trials. Phase I trials should be sufficient, and many have been completed using psilocybin. Rescheduling can help solve this problem by promoting larger trials. An abundance of science and public health data supports it.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

SpeedWeed

SEPTEMBER 17, 2021

The funding will allow MAPS Public Benefit Corporation (MAPS PBC) to activate a team to evaluate the scope of the lack of resources needed for TBI treatment. . Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

NOVEMBER 12, 2021

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. million as of September 30, 2021.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

AUGUST 17, 2021

Most of the Mobile Medical Applications in Clinical Trials are Monitoring Symptoms that can Support Early Disease Diagnosis. Medical Imaging Software Improves Diagnostic Accuracy and Supports Doctors in Designing Better Treatment for Patients. Smart Inhalers Enable High Patient Engagement and Improve Treatment Effectiveness.

Research and Development 98

Research and Development Clinical Trials Concentrates Patients 98

Cannabis Law Report

NOVEMBER 15, 2021

Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments. “We On July 30, 2021, Virpax announced the appointment of Gerald W. On August 17, 2021, Virpax announced that it had received FDA response and guidance on AnQlar.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

DECEMBER 21, 2021

This UK-based company caught our attention in 2021 for its team of renowned psychedelic researchers, including chief research officer Professor David Nutt, chief medical officer Dr. Ben Sessa, and head of ketamine psychotherapy Dr. Celia Morgan, as well as its unique studies into ketamine treatment for addiction and gambling addiction.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

SpeedWeed

AUGUST 11, 2021

Suicide among veterans is an urgent public health crisis, but it’s solvable if we invest in researching new treatments for pain, depression, and PTSD,” said Sisley in a press statement. The grant comes from Michigan’s 2021 Veteran Marijuana Research Grant Program , and is funded by the state’s recreational cannabis taxes.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In May 2021, a Nature Medicine study showed the benefits of MDMA in relieving post-traumatic stress disorder. [4] 5] The Journal of the American Medical Association published similar findings in May 2021. [6].

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

AUGUST 2, 2021

The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.

CBD 105

CBD Data Sleep Clinical Trials 105

The Cannigma

JANUARY 13, 2023

A review of existing endocannabinoid system and migraine research from March 2022 identified many surveys, but fewer clinical research trials, and even fewer double-blind placebo studies. 7 A 2021 study of a medical cannabis cohort reported that high THC / low CBD flower was the most preferred cannabis type in migraine patients.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

DECEMBER 9, 2021

Thu, December 9, 2021, . 9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. NEW YORK , Dec.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

The Cannigma

OCTOBER 19, 2021

A clinical trial published in 2015 found that the test subjects had “significantly higher blood THC” levels when they used cannabis along with alcohol, and combining the two led to increased performance impairment. The researchers added that people in treatment for AUD might benefit from stopping or reducing their cannabis use.

Research and Development 128

Research and Development Clinical Trials Edibles THC 128

Cannabis Law Report

NOVEMBER 29, 2021

In short: IMO COMPASS Pathway is one of the most undervalued & impactful biotech stocks out there – and atai is committed to being the global leader in novel mental health treatments. Published on November 30, 2021. We think the COMPASS Phase 2b trial for Treatment-Resistant Depression (TRD) is a total game-changer.

Treatment 52

Treatment Clinical Trials Data Patients 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. On May 3, 2021, our study of MDMA-assisted therapy for PTSD achieved successful results for patients with severe, chronic PTSD.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

OCTOBER 12, 2021

SAN DIEGO–(BUSINESS WIRE)– #CBD — Radicle Science , a transformative healthtech B-corp validating consumer health products for the first time, secured its initial seed funding in Q4 2020 and surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021. Notably, Peter H.

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

JULY 29, 2021

July 29, 2021 07:29 AM Eastern Daylight Time. Our second quarter results were a strong validation of our strategy as we posted a 250% quarter-over-quarter increase in revenue compared to the first quarter of 2021. TORONTO–( BUSINESS WIRE )–Heritage Cannabis Holdings Corp. Eastern Canada.

Recreational 98

Recreational Vaping Concentrates Clinical Trials 98

Healer

MARCH 26, 2021

March 19, 2021. Gresh has joined a growing number of patients who swear by medical cannabis not only as a treatment option for chronic pain, but also as a substitute for prescription opioids used in pain management. The researchers stressed the need for large, well-designed clinical trials. Others aren’t so sure.

Chronic Pain 86

Chronic Pain Clinical Trials Treatment Patients 86

Cannabis Law Report

JULY 28, 2021

Validates Cepharanthine’s potential in treating various cancers with unsatisfactory treatment options. Advance to FDA IND-enabling studies to support human clinical studies. – July 28, 2021) – PharmaDrug Inc. Toronto, Ontario–(Newsfile Corp.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. 3 Nature Aging | VOL 1 | July 2021 | p. tumor necrosis factor receptor I (TNFRI) and IL-6.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JULY 6, 2021

July 06, 2021 08:30 ET | Source: Ehave. MIAMI, July 06, 2021 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Dr. Bankole Johnson was featured in a March 5 th 2021 Forbes article, “Dr. We look forward to Dr. Johnson’s expertise as we expand our mental health analytical platform and enter clinical trials.”

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

NOVEMBER 12, 2021

Released 07:00:14 01 November 2021. 01 November 2021. 1 November 2021. of the voting rights of KCP in the Company) that on 1 July 2021, KCP was offered a facility of £1,000,000 by Brown Shipley & Co Limited (“Brown Shipley”) by way of an overdraft (the “Facility”). RNS Number : 8293Q.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Canna Care Docs

DECEMBER 16, 2020

It would feel like an out-of-body experience, except for one fact: your body is constantly reminding you of those symptoms you’ve been suffering from all this time, putting treatment on the back burner while you deal with life as we know it. Could medical cannabis help you find the “new you” in 2021? Enough is enough. Chronic pain.

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52